Benchmark Holdings PLC's (LON:BMK) chairman Peter George speaks to Proactive London's Andrew Scott soon after agreeing to sell its vaccine manufacturing assets at its facility in Braintree, UK to Cell and Gene Therapy Catapult. George says he's pleased that Benchmark has been able to be part of the UK solution for vaccine manufacturing.
Benchmark Holdings' Peter George says sale of its vaccine facility is a 'win-win-win'
Quick facts: Benchmark Holdings PLC
Price: 41 GBX
Market Cap: £273.73 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Benchmark Holdings PLC named herein, including the promotion by the Company of Benchmark Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE